ArticleHistology and histopathology2025
Expression pattern, immune signature, and prognostic value of RBM10 in human cancers.
Article in Histology and histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting RBM10-Repressed RORB Activity in Liquid Condensates Inhibits Lysosomal Biogenesis and Neuroblastoma Progression via Affecting NF-κB Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Gastric carcinoma harbouring loss‑of‑function mutations in theOncology letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundRNA-binding motif protein 10 (RBM10) regulates the expression of genes involved in immune responses and is associated with a wide spectrum of cancers. Meanwhile, immunotherapy is the most promising cancer treatment of our time; nevertheless, the pan-cancer role of RBM10 remains to be elucidated.
methodsData from multiple online databases, including ONCOMINE, UALCAN, GEPIA2, Kaplan-Meier Plotter, cBioPortal, STRING, and TIMER were analyzed. The protein expression levels of RBM10 in various tumor types were verified by immunohistochemistry (IHC).
resultsRBM10 is upregulated in multiple tumors compared with the corresponding normal tissues. In addition, RBM10 is highly mutated in various cancers. We also compared the levels of phosphorylated RBM10 between normal and primary tumor tissues. We found that the expression of RBM10 was positively correlated with Programmed cell death 1 (PD-L1) and Cytotoxic lymphocyte antigen 4 (CTLA4) in most cancers, except Thyroid carcinoma (THCA). Moreover, the expression of RBM10 was significantly related to immune cell infiltration in many cancers, suggesting that it is a promising target for cancer immunotherapy.
conclusionsRBM10 expression is closely related to tumor prognosis and the immune microenvironment. Our findings provide new insights into the role of RBM10 in cancer diagnosis and treatment.
Indexed as
Identifiers
39056107What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.